Kim Robert Young 4
4 · 4D Molecular Therapeutics, Inc. · Filed Feb 7, 2024
Insider Transaction Report
Form 4
Kim Robert Young
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-02-05$18.66/sh+12,000$223,920→ 13,595 total - Sale
Common Stock
2024-02-05$30.05/sh−552$16,588→ 1,043 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-05−6,000→ 64,000 totalExercise: $15.78Exp: 2032-01-31→ Common Stock (6,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-05−6,000→ 54,000 totalExercise: $8.04Exp: 2032-08-31→ Common Stock (6,000 underlying) - Exercise/Conversion
Common Stock
2024-02-05$15.78/sh+6,000$94,680→ 7,595 total - Exercise/Conversion
Common Stock
2024-02-05$8.04/sh+6,000$48,240→ 7,595 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-05−12,000→ 138,000 totalExercise: $18.66Exp: 2030-11-08→ Common Stock (120,000 underlying) - Sale
Common Stock
2024-02-05$30.05/sh−12,000$360,600→ 1,595 total - Sale
Common Stock
2024-02-05$30.05/sh−6,000$180,300→ 1,595 total - Sale
Common Stock
2024-02-05$30.05/sh−6,000$180,300→ 1,595 total
Footnotes (4)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023.
- [F2]25% of the shares subject to the option vest on the first anniversary measured from October 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest and become exercisable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
- [F3]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
- [F4]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.